Journal of Immunology Research / 2016 / Article / Tab 2

Clinical Study

HLA-01:03 Allele in Lung Transplant Recipients Correlates with Higher Chronic Lung Allograft Dysfunction Occurrence

Table 2

Baseline comparison of distribution and risk factors for 119 patients who underwent LTx according to HLA-E genotypes.

E01:01/01:01E01:01/01:03E01:03/01:03p01:01/01:01E01:03 allelep

Genotypes frequency (, %)38 (31.9)57 (47.9)24 (20.2)38 (31.9)81 (68.1)
Male (, %)15 (40)28 (49)12 (50)0.6015 (39.5)40 (49)0.33
Age of recipient (SD)39.1 (14.2)40.23 (13)39.6 (12)0.9239.1 (14.2)40 (13)0.72
Initial disease0.330.91
 Emphysema (, %)10 (26.3)11 (19.3)10 (41.7)10 (26.3)21 (25.9)
 Fibrosis (, %)8 (21.1)8 (14)5 (20.8)8 (21.1)13 (16.1)
 Cystic fibrosis (, %)14 (36.8)28 (49.1%)6 (25%)14 (36.8)34 (42.1)
 Others (, %)6 (15.8)10 (17.5%)3 (12.5)6 (15.8)13 (16)
Transplant procedure0.580.92
 Lung and heart transplantation (, %)1 (2.6)0 (0)1 (4.2)1 (2.6)1 (1.2)
 Single lung transplantation (, %)8 (21.1)14 (24.6)4 (16.7)8 (21.1)18 (22.2)
 Bilateral lung transplantation (, %)29 (76.3)43 (75.4)19 (79.2)29 (76.3)62 (76.5)
CMV status
 D+/R− (, %)6 (16.2)7 (12.3)4 (17.4)0.836 (16.2)11 (13.8)0.78
 D+/R+ or − (, %)19 (51)31 (54)9 (40)0.4619 (51)40 (50)0.88
 D+ or −/R+ (, %)22 (58)36 (63)12 (50)0.5422 (58)48 (59)0.88
 Mismatch HLA/6 ()5.0354.830.95.034.950.90
Infection at M1 (, %)8 (53.3)16 (47.1%)2 (25)0.498 (53.3)18 (42.9)0.48
Infection at M3 (, %)6 (46.2)7 (38.9)5 (50)0.836 (46.2)12 (42.9)0.84
Infection in first year (, %)16 (42)32 (56)11 (45.8)0.3716 (42.1)43 (53.1)0.26
DSA at M1 (, %)7 (63.6)13 (81.3)5 (83.3)0.517 (63.5)18 (81.8)0.25
DSA at M3 (, %)6 (66.7)8 (66)3 (60)16 (66.7)11 (64.7)0.92
CLAD occurrence (, %)5 (22.7)20 (40.8)7 (58.3)0.065 (22.7)27 (44.3)0.02
BOS (, %)5 (23.8)16 (32.7)6 (22.2)0.315 (23.8)22 (36.1)0.02
RAS (, %)0 (0)4 (8.2)1 (8.3)0.410 (0)5 (8.2)0.32
Overall survival (median, year)2.373.72.60.01

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.